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To identify mechanisms whereby activating tran-
scription factor 2 (ATF2) alters the radiation resistance
of human melanoma cells, we examined the possible role
of ATF2 in UVC-induced apoptosis. Forced expression of
full-length or truncated (D1–195 amino acids) forms of
ATF2 in LU1205, a late-stage human melanoma cell line,
elevated the levels of UVC-induced apoptosis. At the
same time, either truncated or full-length forms of ATF2
reduced UVC-induced activation of the tumor necrosis
factor-a (TNFa) promoter and decreased expression of
TNFa. Forced expression of c-Jun in ATF2-expressing
melanoma cells restored TNFa expression, suggesting
that both forms of ATF2 sequestered transcription fac-
tors that positively regulate TNFa expression in re-
sponse to UV irradiation. Antagonistic antibodies to
Fas, but not to TNFR1, efficiently suppressed UVC-in-
duced apoptosis, suggesting that the Fas pathway medi-
ates the primary apoptotic signal in melanoma cells
whereas the TNFR1 pathway elicits a survival signal.
Indeed, treatment of melanoma cells with TNFa before
UVC irradiation partially suppressed UVC-induced ap-
optosis, further supporting the protective role of TNFa
in UVC-treated melanoma cells. Taken together, our
findings suggest that ATF2 contributes to UVC-induced
apoptosis through transcriptional silencing of TNFa,
which balances Fas-mediated cell death in melanoma.
Programmed cell death (apoptosis) is a common cellular re-
sponse to stress caused by environmental challenges (1). Al-
tered expression of apoptosis-related proteins, which coincides
with decreased or absent apoptosis, is commonly observed in
various tumor types and is of fundamental importance in tu-
mor resistance to host defenses as well as to clinical therapy
(2). Indeed, reduced ability of tumors to undergo apoptosis is
often associated with elevated drug resistance and poor clinical
outcomes. Malignant melanoma is a primary example of a
cancer that responds poorly to various treatments, including
chemotherapy and g-irradiation (3). Despite the alarming in-
crease in the incidence of this tumor in the past decade, the
molecular mechanisms of its progression as well as the regu-
lation of apoptosis in human melanoma remain largely un-
known (4).
The mechanisms underlying apoptotic signaling have been
intensively studied in recent years. Two cell surface molecules,
Fas and TNFR1,1 represent the main death signaling receptors
(1). Receptor trimerization by ligands FasL and TNFa, respec-
tively, initiate receptor interaction with the intermediate sig-
naling molecules FADD and FLICE (caspase-8), followed by
activation of the caspase cascade (1, 5, 6). In addition to its role
in apoptosis, TNFR1-mediated signaling is also linked with the
regulation of survival functions, including induction of cyto-
kines, growth factors, and cell proliferation and differentiation
(7–9). Furthermore, TNFa appears to be one of the primary
growth regulators of metastatic cancer cells (10, 11), including
late-stage melanoma cells (12–14). Hence, suppression of TNF
signaling may enhance the apoptotic stimulus to tumor cells.
Key to understanding the interplay between TNFa and Fas
signaling is the nature of their upstream transcriptional regu-
lators and downstream targets (i.e. inhibitors of apoptosis and
survival proteins) in concordance with, or independent of, NF-
kB-dependent signaling (15–17). Expression of the human
TNFa gene is controlled by the AP-1, ATF2, Erg-1, C/EBPb,
and NF-kB transcription factors (18–22). Transcriptional reg-
ulation of Fas and FasL genes was shown to be mediated by
NF-kB, AP-1, NF-AT, ATF2, and Egr3 (23–26). As a dynamic
process, programmed cell death is dependent, in many cases,
on new gene expression (27), and is tightly regulated at the
transcriptional level (28–30).
Our interest in exploring mechanisms underlying key mela-
noma phenotypes led us to identify CREB/ATF transcription
factors as regulatory proteins that play important roles in
determining both melanoma’s resistance to radiation and its
metastatic potential (31, 32). ATF2, a member of the ATF/
CREB family of basic region leucine zipper (bZIP) DNA-binding
proteins (33–35), was shown to modulate melanoma’s resist-
ance to UVC irradiation but not to contribute to its metastatic
potential (36). ATF2 is among several transcription factors,
including AP-1, CREB, and Rel/NF-kB, which have been found
to be UV-inducible. ATF2 induction in response to stress occurs
at the levels of transcription-translation and posttranslational
modification, the latter of which is mediated by JNK/p38 ki-
nases (37, 38). ATF2 has been implicated in the transcriptional
control of various stress-responsive genes, including c-Jun (39),
interferon-b (40), urokinase (41), TGF-b2 (42), TNFa (18, 20),
and DNA polymerase b (43). Differential splicing of ATF2 cre-
ates several isoforms which exhibit different transcriptional
outputs (44). Full-length ATF2 is transcriptionally inactive in
its native form as a result of intramolecular interaction of its
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DNA-binding domain with the amino-terminal transactivation
domain (33). ATF2 as well as a related factor, ATFa, not only
can form DNA-binding homodimers but also can efficiently
heterodimerize with members of the ATF/CREB and Jun/Fos
families, thus providing an important transcriptional control
mechanism (41, 45–47). Duration and magnitude of ATF2
transcriptional output are also regulated at the level of phos-
phorylation and stability. While stable in its native non-active
form, ATF2 is a short-lived protein after homo- or heterodimer-
ization. ATF2 instability is further facilitated by heterodimer-
ization with certain partners, which provide additional target-
ing molecules for ubiquitination through their own docking
sites, as shown for c-Jun (48).
To identify mechanisms underlying ATF2’s ability to modu-
late radiation resistance, we studied the possible role of ATF2
in apoptosis of human melanoma cells. We demonstrate that
ATF2 expression increases UV-mediated apoptosis through
suppression of TNFa expression, which elicits survival signals
in tumors of this type.
EXPERIMENTAL PROCEDURES
Cell Lines—Human melanoma LU1205 cells were maintained in
MCDB153/L15 medium (4:1) supplemented with 5% fetal bovine serum,
L-glutamine, and antibiotics. LU1205/neo, LU1205/ATF2, LU1205/
ATF2D1–195, and LU1205/IkBD cell lines were maintained in the same
medium supplemented with G418 (200 mg/ml). Cells were grown at
37 °C with 5% CO2.
Stable Transfection and Selection—The expression vectors pECE-
ATF2 encoding full-size ATF2 and pECE-ATF2D1–195, a truncated
form of ATF2 cDNA lacking the first 195 amino acids and fused with
GAL4 (34, 35), were transfected by electroporation (230 V, 1050 micro-
farads) into LU1205 cells together with pBK-RSV-neo plasmid (Strat-
agene, La Jolla, CA) as described previously (36). In parallel, the pECE
vector was cotransfected with pBK-RSV-neo to generate control
LU1205/neo cells. The expression vector pCMV4-IkBD (49) plus
pcDNA3-neo (Invitrogen, Carlsbad, CA) was also cotransfected by elec-
troporation into LU1205 cells. LU1205/neo, LU1205/ATF2, LU1205/
ATF2D1–195, and LU1205/IkBD cell lines were created as a mixed
population of G418-resistant clones.
Transient Transfection and Luciferase Assay—Reporter constructs
(20 mg) were transiently cotransfected with the indicated expression
vectors and pCMV-b-gal (5 mg) into 107 LU1205 melanoma cells by
electroporation (230 V, 1050 microfarads; Gene Pulser, IBI). The re-
porter constructs used were: 5xJun2tk-Luc and vector tk-Luc (50);
2615 TNF-Luc, 2615 TNF(mutCRE)-Luc, 2615 TNF(mutAP-1)-Luc,
236 TNF-Luc (19), 2453 FasL-Luc, 2318 FasL-Luc, 2237 FasL-Luc
(23), 21.3kb FasL-Luc, and variants of this construct with mutations in
the NF-kB- and AP-1 sites (24). Expression constructs pECE-ATF2,
pECE-ATF2D1–195 (34, 35), pCMV-c-Jun-HA (51), and TAM67, a dom-
inant negative form of c-Jun (52, 53), were also used in these experi-
ments. Luciferase activity was determined using the Promega lucifer-
ase assay system (Promega, Madison, WI). Luciferase activities were
normalized on the basis of b-galactosidase levels in transfected cells.
Transient Transfection and GFP Assay—Melanoma cells (6 3 106)
were transiently cotransfected with either ATF-2- or TAM-67 expres-
sion vectors together with marker plasmid encoding green fluorescent
protein, pGFP (CLONTECH), 10 and 2.5 mg, respectively, by electropo-
ration. Twenty-four hours after transfection cells were irradiated by
UVC (60 J/m2) and 18 h after treatment were stained with PI and
analyzed using flow cytometry. The ratio of GFP1PI1 to total GFP1
cells was used to measure frequencies of death in the transfected cells.
Transient Transfection and X-gal Staining—Melanoma cells (6 3
106) were transiently cotransfected with ATF2 expression vectors and
pCMV-b-gal (10 and 2.5 mg, respectively) by electroporation. Twenty-
four hours after transfection, cells were irradiated with UVC (60 J/m2)
as described previously (32). To identify b-galactosidase activity, cells
were fixed 18 h after UVC treatment and stained with X-gal (28). The
ratio of blue cells with apoptotic morphology to the total number of blue
cells served as the indicator of the level of apoptosis in transfected cells.
Cell Treatment and Apoptosis Studies of Stably Transfected Mela-
noma Cells—Cycloheximide (10 mg/ml), actinomycin D (200 ng/ml) (Sig-
ma), and the caspase inhibitor, zVAD-fmk (10–50 mM) (Enzyme Sys-
tems, Dublin, CA) were added as indicated. The proteasome inhibitor
lactacystin was purchased (Dr. E. J. Corey, Harvard University, MA)
and used at 10 mM. Recombinant TNFa (PharMingen, San Diego, CA)
was used at a final concentration of 1–4 ng/ml. Antagonistic monospe-
cific antibodies against Fas (clone G254-274 from PharMingen) and
against TNFR1 (clone 16803.1 from R&D Systems, Minneapolis, MN)
were added as indicated at the final concentration of 1–5 mg/ml.
Annexin-V-FITC staining in the presence of PI was performed for
detection of early apoptosis levels using TACS Annexin-V-FITC kit
(Trevigen, Gaithersburg, MD). Flow cytometric analysis was performed
on an Epics-Profile II flow cytometer (Coulter, Hialeah, FL) with Elite
software 4.01 by analyzing 104 cells/sample, using wide scatter gates to
include late apoptotic cells.
DNA fragmentation analysis was performed as described previously
(54). Cells were pelleted and resuspended in 0.5 ml of hypotonic buffer
with 0.1% Triton X-100 containing propidium iodide (PI) (40 mg/ml) and
DNase-free RNase A (1 mg/ml). Cells were incubated at 37 °C for 30 min
and analyzed on an Epics-Profile II flow cytometer (Coulter). The per-
centage of cells to the left of the diploid G0/1 peak, diagnostic of hypo-
diploid cells that have lost DNA, was taken as the percentage of apop-
totic cells. The analysis was performed without light scatter gating.
Western Blotting Analysis—Total cell extracts were resolved on 10%
SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose,
and processed by standard methods. The polyclonal anti-PARP serum
(Biomol, Plymouth Meeting, PA) was used at a 1:1000 dilution. Poly-
clonal Abs against ATF2 and phosphoATF2 (New England Biolabs)
were used at a 1:1000 dilution. Monoclonal Abs against human TNFa
(clone Mab1), Fas (clone G254–267) (PharMingen), and TNFR1(R&D
System), and polyclonal Abs against FasL and IkBa (Santa-Cruz Bio-
technology) were used at the same dilution. The secondary Abs were
goat anti-rabbit IgG or goat anti-mouse IgG conjugated to horseradish
peroxidase (dilution 1:5000). Signals were detected using the ECL sys-
tem (Amersham Pharmacia Biotech).
RESULTS
Characterization of UVC-induced Apoptosis in Human Mel-
anoma Cells—To study regulation of UVC-induced apoptosis in
melanoma, we used the LU1205 cell line, which represents a
late stage melanoma that harbors wild type p53. These cells
exhibit higher resistance to irradiation than early stage mela-
noma cells (55). The finding that expression of a truncated
ATF2 form (D1–195) reduced radiation resistance of late-stage
melanoma cells (36) prompted our interest in elucidating mech-
anisms by which ATF2 may elicit such changes. Since radiation
resistance may be inversely correlated with the degree of pro-
grammed cell death, we studied the possible role of ATF2 in
UV-induced apoptosis of these melanoma cells.
Several markers of apoptosis were used to monitor and char-
acterize UVC-mediated programmed cell death in melanoma
cells. To distinguish between early and late phases of apopto-
sis, annexin-V-FITC and PI staining, which detect early and
late phases of apoptosis (56), respectively, were used. Eighteen
hours after UVC irradiation, 20% of LU1205 melanoma cells
were annexin-V1, of which 11% were annexin-V1PI2 and 9%
annexin-V1PI1, reflecting the early and late phases of apopto-
sis, respectively (Fig. 1A). In several independent experiments,
we found that 25 6 6% LU1205 cells were annexin-V1 (apop-
totic) 18 h after UVC irradiation, compared with 5 6 3% for
nontreated cells. DNA fragmentation analysis, performed by
staining cell nuclei with PI and determining the percentage of
apoptotic cells with hypodiploid DNA content (Fig. 1B), re-
vealed that 36% of the total cell population had apoptotic nuclei
with hypodiploid DNA content 40 h after UVC irradiation,
compared with 2% for nontreated cells (Fig. 1B). Within 3 days
after treatment the apoptosis level reached 70%; the vast ma-
jority of melanoma cells died 4 days after irradiation (data not
shown). Cycloheximide (Fig. 1C) as well as actinomycin D (data
not shown) partially suppressed UVC-induced apoptosis of mel-
anoma cells, indicating that UVC-induced gene expression is
required if maximal levels of apoptosis are to be achieved.
Since caspase-dependent proteolysis has been shown to play
an important role in different types of programmed cell death
(5), we determined the possible role of activation of the caspase
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cascade following UVC irradiation of melanoma cells. A 50 mM
quantity of zVAD-fmk, a caspase inhibitor, substantially sup-
pressed UVC-induced apoptosis (Fig. 1, A and B). To monitor
cleavage of poly(ADP-ribose) polymerase (PARP), a typical tar-
get of caspase-3 and an indicator of early apoptotic commit-
ment (57), immunoblot analysis of nuclear proteins from UVC-
treated melanoma cells was performed with the aid of anti-
PARP Ab, revealing the presence of the 85-kDa cleavage
product 18 h after UVC treatment, but not in the presence of
zVAD-fmk (Fig. 1D).
The role of proteasome-dependent degradation in UVC-me-
diated apoptosis of melanoma cells was examined using the
proteasome inhibitor lactacystin (58). Whereas 10 mM lactacys-
tin did not induce apoptosis in nonstressed melanoma cells
(data not shown), a substantial increase in UVC-induced apop-
tosis was seen in the presence of 10 mM lactacystin, indicating
a protective role of proteasome-dependent protein degradation
in UVC-induced apoptosis (Fig. 1A). Increased PARP cleavage
was seen in lactacystin-treated cells following UVC irradiation
(Fig. 1D). These observations suggest that all three major cell
regulatory processes (new gene expression, proteasome-dependent
protein degradation, and caspase proteolysis) contribute to UVC-
induced apoptosis of melanoma cells.
Role of ATF2 in UVC-induced Gene Response and Apoptosis
of Human Melanoma Cells—To elucidate a probable function of
ATF2 in the regulation of UVC-induced apoptosis of human
melanoma cells, we utilized expression vectors encoding either
GAL4 fused with truncated ATF2 lacking the transactivation
domain (pECE-ATF2D1–195) or full-size ATF2 (pECE-ATF2)
(34, 35). To monitor ATF2-mediated transactivation, a reporter
construct containing five repeats of the ATF-2/AP-1 binding
site from the Jun promoter (TRE-Jun2), which preferentially
bind ATF2/Jun heterodimers (39, 50), was used. ATF2/AP-1-
dependent luciferase activity increased 3-fold after UVC irra-
diation of control LU1205 cells. Transient transfection of trun-
cated ATF2 (at a 2:1 ratio of expression vector to reporter
construct) slightly increased the basal level of ATF2/AP-1-de-
pendent transcription but decreased UVC-induced transactiva-
tion of ATF2/AP-1 (25–30%, compared with control cells; Fig.
2A). In contrast, expression of full-size ATF2 up-regulated the
basal level of ATF2/AP-1-dependent luciferase activity 2.5-fold.
Unexpectedly, the transfected full-size ATF2 also decreased
FIG. 1. UVC irradiation induces
melanoma cell apoptosis. A, LU1205
cells were treated with UVC at 60 J/m2 in
the presence of zVAD-fmk (50 mM) and
lactacystin (10 mM), added 1 h before irra-
diation and also in the absence of these
materials. The percentage of early apop-
tosis was determined 18 h after UVC
treatment using annexin-V-FITC plus PI
staining and flow cytometry. The percent-
age of stained cells is shown near each
quadrant. Quadrant 3 contains Annexin-
V2PI2 (live) cells. Annexin-V1PI2 and
annexin-V1PI1 cells indicate early and
late phases of apoptosis, respectively. B,
DNA fragmentation analysis of LU1205
cells was performed 40 h after UVC treat-
ment, as described under “Experimental
Procedures.” The percentage of cells in
gate 1 indicates the level of apoptotic cells
with hypodiploid DNA content. C, effect of
cycloheximide (CHX) (10 mg/ml) on UVC-
induced apoptosis of LU1205 cells. The
percentage of early apoptosis (annexin-
V1PI2) is shown. D, UVC-induced cleav-
age of PARP. Western blot analysis of
PARP was performed 18 h after UVC ir-
radiation (40 J/m2 for lane 1 and 60 J/m2
for lanes 2–7) of LU1205 cells in absence
or presence of zVAD-fmk (50 mM), lacta-
cystin (10 mM) or PMA (10 ng/ml). The
position of intact (116 kDa) and cleaved
(85 kDa) forms of PARP is indicated by
arrows.
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UVC-induced ATF2/AP-1-mediated transactivation (Fig. 2A).
These observations suggest that both truncated and full-size
ATF2 after transfection exert a certain silencing effect on UVC-
induced ATF2/AP-1-dependent transcription in melanoma
cells.
We next determined whether transcriptional suppression by
ATF2 alters the degree to which melanoma cells undergo ap-
optosis in response to UV irradiation. Apoptosis studies were
performed by cotransfection of ATF2 expression vectors with
either pGFP or pCMV-b-gal encoding green fluorescent protein
and b-galactosidase, respectively, as marker genes. To deter-
mine the frequency of death in ATF2-transfected cells, UVC-
irradiated and nontreated cells were stained with PI and ana-
lyzed by flow cytometry, allowing quantification of GFP1PI1
cells in the overall population of GFP1 cells. Expression of
either full-length or truncated forms of ATF2 notably increased
(1.8- and 1.3-fold, respectively) the frequency of cell death
following UVC irradiation of LU1205 cells (Fig. 2B). Parallel
analysis using X-gal staining of b-galactosidase-expressing
cells enabled visual detection of blue cells with apoptotic mor-
phology in the total population of blue cells (28), revealing a
similar increase in apoptosis levels after UVC irradiation in
ATF2-transfected cells (data not shown).
To further investigate ATF2-dependent regulation of UVC-
induced apoptosis of human melanoma cells, we established
LU1205 cell lines stably transfected with either full-size ATF2
cDNA (LU1205/ATF2 cells) or the truncated form, GAL4-
ATF2D1–195 (LU1205/ATF2D1–195), as well as the control cell
line transfected with the empty vector and neo marker plasmid
(LU1205/neo). Western blot analysis confirmed elevated ex-
pression of the respective forms of ATF2. Cells that constitu-
tively express the full-size ATF2 revealed increased levels of
68-kDa ATF2 as well as spliced isoforms, before and after UVC
irradiation (Fig. 3A). However, immunoblot with anti-phospho-
ATF2 (Thr71) Ab revealed the same level of phosphorylated
forms of ATF2 after UVC irradiation of LU1205/ATF2 cells,
indicating a relative decrease in the ratio of phospho-ATF2 to
FIG. 2. Modulation of ATF2-dependent transcription affects
UVC-induced apoptosis of melanoma cells. A, 8 3 106 LU1205 cells
were transiently cotransfected with the reporter construct 5xJun2tk-
Luc (5 mg) and expression vector pECE, pECE-ATF2, or pECE-
ATF2D1–195 (10 mg) in the presence of pCMV-b-gal (5 mg). Cotransfec-
tion with tk-Luc (5 mg) was used as a control for basal luciferase
activity. Transfected cells were divided into two plates. Twenty-four
hours after transfection, half the plates were irradiated with UVC (60
J/m2). After an additional 18 h, irradiated and nontreated cells were
analyzed for luciferase and b-galactosidase activities. The normalized
ratio of luciferase activity to b-galactosidase is shown. B, LU1205 cells
were transiently transfected with pECE, pECE-ATF2, or pECE-
ATF2D1–195 (20 mg) in the presence of pGFP (5 mg). Transfected cells
were divided into two plates. Twenty-four hours after transfection, half
the plates were irradiated with UVC (60 J/m2). After an additional 18 h,
irradiated and nontreated cells were stained with PI and analyzed by
flow cytometry. The ratio of PI1 GFP1 cells to all GFP1 cells indicates
the frequency of apoptotic cells in the population of transfected cells.
FIG. 3. A, total extracts of stably transfected cell lines LU1205/ATF2
and LU1205/neo were analyzed by Western blotting with anti-ATF2
and anti-phospho-ATF2 Abs. Positions of p68, p55, p50, and p42 forms
of ATF2 and phosphorylated p68* p50*, and p42* forms are indicated
by arrows. B, effect of modulation of ATF2 levels in stably transfected
melanoma cell lines (LU1205/ATF2, LU1205/ATF2D1–195, and
LU1205/neo) on transcriptional activity of the ATF2-dependent re-
porter constructs. 107 LU1205/neo, LU1205/ATF2, and LU1205/
ATF2D1–195 cells were transiently transfected with 5xJun2tk-Luc (20
mg) in the presence of pCMV-b-gal (5 mg). Twenty-four hours after
transfection, cells were irradiated with UVC, and, after an additional
18 h, luciferase and b-galactosidase activity were determined. The
normalized ratio of luciferase to b-galactosidase activity is indicated.
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total ATF2 (Fig. 3A). Immunoprecipitation with anti-GAL4 and
subsequent Western blotting with anti-ATF2 Ab further con-
firmed the presence of the fused truncated form of ATF2 in
LU1205/ATF2D1–195 cells (data not shown), as was observed
previously with MeWo melanoma cells transfected with
ATF2D1–195 (36).
We next examined transcriptional regulation of a reporter
construct containing ATF2/AP-1 binding sites (5xJun2tk-Luc)
in LU1205/ATF2 and LU1205/ATF2D1–195 cells. In agreement
with the results of transient transfection studies, LU1205/
ATF2 cells possessed increased basal levels of ATF2/AP-1-de-
pendent luciferase activity and decreased UVC-induced levels
of this activity (30–35%) compared with control cells. UVC-
induced ATF2-dependent luciferase activity was also decreased
(20–25%) in LU1205/ATF2D1–195 cells (Fig. 3B).
To monitor apoptosis in cell lines stably transfected with
ATF2 constructs, we used Annexin-V staining and DNA frag-
mentation analysis. As found in the apoptosis study of tran-
siently transfected cells, annexin-V plus PI staining (Fig. 4A)
showed increased levels of cell death in both LU1205/ATF2 and
LU1205/ATF2D1–195 cells compared with the control LU1205/
neo cells 16–24 h after UVC irradiation. UVC-induced apopto-
sis levels (annexin-V1) were enriched 21 6 2%, 30 6 3%, and
32 6 3% relative to control LU1205/neo, LU1205/ATF2D1–195,
and LU1205/ATF2 cells, respectively, 24 h after UVC irradia-
tion (60 J/m2), based on the results of four independent exper-
iments. DNA fragmentation analysis showed an additional in-
crease of apoptosis levels 40 h after UVC treatment for
LU1205/ATF2 (64 6 10%), compared with LU1205/ATF2D1–
195 (31%) and control (24 6 4%) cells (Fig. 4B). These obser-
vations suggest that expression of either truncated or full-size
ATF2 increase the level of UV-induced apoptosis in LU1205
melanoma cells. Interestingly, full-length ATF2 elicited a
greater increase than the amino-terminal truncated form.
Effect of ATF2 on UVC-induced TNFa Expression—Meta-
static melanomas actively produce a set of cytokines, including
TNFa, that appear to provide autocrine growth conditions (13,
14, 59). Indeed, luciferase activity driven by TNFa promoter
FIG. 4. UVC-induced apoptosis of
LU1205 cells stably transfected with
ATF2 constructs. LU1205/neo, LU1205/
ATF2, and LU1205/ATF2D1–195 cells
were irradiated with UVC (60 J/m2). A,
apoptosis levels were determined using
annexin-V-FITC plus PI staining 3–24 h
after treatment. B, DNA fragmentation
analysis was performed 40 h after treat-
ment as described under “Experimental
Procedures.”
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(2615 TNF-Luc) (19), was up-regulated (5–7-fold) after UVC
irradiation of LU1205 cells (Fig. 5A). Mutation in the CREB/
AP-1 site (at the 2106 position) of this construct partially
abrogated this increase (by 40–60%). In contrast, mutation
within the AP-1 binding site (at the 266 position) was less
pronounced (Fig. 5A), suggesting that the CREB/AP-1 site (at
2106) is the primary regulator of TNFa expression in mela-
noma cells, possibly via ATF2, as was described previously for
other cell systems (18–20).
To confirm the role of ATF2 in regulation of TNFa expression
in the melanoma cells, LU1205 cells were transiently cotrans-
fected with the 2615 TNF-Luc reporter construct and either
full-size or truncated ATF2 expression vectors. Both ATF2
constructs reduced the degree of UVC-mediated transactiva-
tion by the TNFa promoter in a dose-dependent manner (Fig.
5B). That full-length (although hypophosphorylated upon UV
irradiation; Fig. 3A) and truncated (without transactivator do-
main) forms of ATF2 elicit the same silencing effect on TNFa
transcription could be attributed to squelching of a positive
factor as a result of efficient heterodimerization with other
bZIP family members. Among the primary transcription factors
that associate with ATF2 is c-Jun (39, 47), which was also
shown to increase TNFa transcription via the CRE/AP-1 site,
following stimulation of monocytes by lipopolysaccharide (21).
We therefore tested the possible effect of c-Jun on TNFa tran-
scription in ATF2-expressing melanoma cells. To this end tran-
scriptional activity of c-Jun was blocked by using a dominant
FIG. 6. A, c-Jun transactivates TNFa promoter activity in LU1205
cells. Effect of full-length and truncated forms of ATF2 on c-Jun-de-
pendent transactivation of TNFa promoter activity. LU1205 cells were
transiently cotransfected with 2615 TNF-Luc (5 mg) in the presence or
absence of 10 mg of pECE-ATF2 and pECE-ATF2D1–195 and indicated
quantities of the pCMV-c-Jun expression construct and 5 mg of b-galac-
tosidase. Luciferase and b-galactosidase activities were determined
after UVC treatment, as described in the legend to Fig. 2. B, c-Jun
partially suppressed UVC-induced apoptosis, which was accelerated by
ATF2D1–195 expression. LU1205 cells were cotransfected with either
pECE-ATF2D1–195 (20 mg) or with this vector and pCMV-c-Jun-HA (10
mg or 20 mg) in the presence of GFP marker plasmid. Two days after
transfection, cells were UVC irradiated. Apoptosis levels of GFP-posi-
tive cells were detected using flow cytometry after PI staining.
FIG. 5. A, effect of mutations of the CRE (2106) and AP-1 (266) sites
on TNFa promoter activity in LU1205 cells. LU1205 cells were tran-
siently cotransfected with 2615 TNF-Luc, 2615 TNF(mutCRE)-Luc, or
2615 TNF(mutAP-1)-Luc reporter constructs. B, effect of altered ATF2
levels on TNFa promoter activity. 107 LU1205 cells were transiently
cotransfected with 2615 TNF-Luc reporter construct (5 mg) and with
indicated amounts of the expression vectors pECE-ATF2, pECE-
ATF2D1–195, or with pCMV-TAM67, a dominant negative mutant of
c-Jun, in the presence of pCMV-b-gal (5 mg). The total quantity of DNA
for transfection was adjusted to 30 mg with vector DNA. The normalized
ratio of luciferase to b-galactosidase activity was determined 18 h after
UVC treatment.
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negative c-Jun construct, TAM-67, which lacks the first 200
amino acids (52, 53), similar to the truncated ATF2 form used
in the present study. Expression of TAM67 in LU1205 sup-
pressed TNF promoter-dependent luciferase activity (Fig. 5B)
as well as increased apoptosis (data not shown). Conversely,
transfection of wild type c-Jun resulted in a dose-dependent
increase of TNFa promoter activity in both non-treated and
UVC-irradiated cells (Fig. 6A). Furthermore, forced expression
of wild type c-Jun partially abrogated the negative effect of
both full-length and truncated forms of ATF2 on TNFa pro-
moter activity (Fig. 6A). c-Jun expression in LU1205 cells (co-
transfected with the GFP marker plasmid) also blocked the
increase in UVC-induced apoptosis caused either by ATF2D1–
195 (Fig. 6B) or full-length ATF2 overexpression (data not
shown). These observations suggest that the ability of ATF2 to
increase the degree of UVC-induced apoptosis is mediated via
suppression of positive transcription factors, such as c-Jun.
Analysis of TNFa promoter activity in stably transfected
LU1205/ATF2 cells further confirmed the data obtained by
transient transfection. LU1205/ATF2 cells exhibited reduced
(35–40%) TNFa promoter activity after UVC treatment (with-
out changes in basal levels) (Fig. 7A). Decrease in TNFa tran-
scription coincided with down-regulation of TNFa protein lev-
els. Western blot analysis revealed a UVC-dependent increase
in the level of TNFa protein (p17) in LU1205/neo cells, whereas
this increase was substantially suppressed in LU1205/ATF2
cells (Fig. 7B). Expression of TNFR1 (whose transcription is
positively regulated by TNFa) was also decreased in LU1205/
ATF2 cells prior to and after UV irradiation compared with
control cells while TRAF2 (60) levels were relatively stable
(data not shown).
Role of TNFR and Fas-mediated Signaling in UVC-induced
Apoptosis of ATF2-expressing Melanoma Cells—To determine
which death-signaling pathway mediates UVC-induced apop-
tosis in control and ATF2-expressing melanoma cells, antago-
nistic mAbs to either TNFR1 or Fas that block the relevant
signaling cascade were added to cell cultures 1 h before UVC
irradiation. Addition of anti-TNFR1 mAb further increased the
degree of apoptosis after UVC irradiation of control and ATF2
(both full-length and truncated forms) transfected cells. Con-
versely, anti-Fas mAb substantially suppressed apoptosis in
these melanoma cells (Fig. 8A). These results point to the
pro-apoptotic role of Fas signaling and anti-apoptotic role of
TNFR-mediated signaling for LU1205/neo, LU1205/ATF2, and
LU1205/ATF2D1–195 cells following UVC irradiation. To con-
firm the protective role of TNFR1-mediated signaling, mela-
noma cells were pretreated with recombinant TNFa before
UVC irradiation. The presence of TNFa (2–4 ng/ml) in the
medium partially reduced the degree of UVC-mediated apop-
tosis of control and ATF2-transfected melanoma cells (Fig. 8B).
These observations demonstrate that TNFa activates a sur-
vival signal in melanoma cells, which is suppressed upon ATF2
expression.
Suppression of UVC-induced TNFa promoter activity by
both the truncated and the full-length forms of ATF2, in tran-
sient transfection as well as in LU1205/ATF2 cells (followed by
down-regulation of TNFa expression), coincided with increased
levels of UV-mediated cell death and pointed to a causal link-
age between ATF2 and regulation of cell death in melanoma. It
is important to note, however, that full-length ATF2 was more
efficient in elevating the degree of UVC-induced apoptosis of
melanoma cells than the truncated form of ATF2. Since the
full-length form of ATF2 is also expected to bring about positive
FIG. 7. A, determination of TNFa promoter activity in stably trans-
fected melanoma cell lines (LU1205/ATF2, LU1205/ATF2D1–195, and
LU1205/neo). These cells were additionally transiently cotransfected
with 2615 TNF-Luc or 236 TNF-Luc constructs (25 mg). UVC treat-
ment and determination of luciferase activity were performed as de-
scribed above. B, Western blot analysis of TNFa and TNFR1/p60 ex-
pression in ATF2-transfected LU1205 cells.
FIG. 8. A, effect of antagonistic anti-Fas and anti-TNFR1 mAbs on
UVC-induced apoptosis of control LU1205/neo, LU1205/ATF2, and
LU1205/ATF2D1–195 cells. Cells were pretreated with 5 mg/ml of the
indicated mAb 1 h before UVC irradiation (60 J/m2). Abs were main-
tained in the medium after UVC treatment. Cells were stained with
annexin-V-FITC plus PI and analyzed using flow cytometry 18 h after
UVC treatment. The percentage of annexin-V-positive (apoptotic) cells
is shown. B, effect of TNFa on UVC-induced apoptosis of LU1205 cell
lines. Cells were pretreated with TNFa (4 ng/ml) 1.5 h before UVC
irradiation. TNFa was maintained in the medium after irradiation. The
percentage of annexin-V-positive (apoptotic) cells is shown.
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transcriptional output, we performed experiments to deter-
mine whether the apoptotic signal in melanoma cells, namely
the Fas pathway, may be also affected by ATF2. Melanoma cell
lines, including LU1205, express both the death receptor and
its ligand, Fas and FasL (Ref. 61 and Fig. 9D). The human FasL
promoter contains two NF-AT sites at positions 2279 and 2140
(23, 62), MEKK-RE (at 2336), which binds ATF2-Jun het-
erodimers (63), and AP-1- and NF-kB-binding sites at positions
21088 and 21050, respectively (23, 24). Transfection of nested
deletions of 59 FasL promoter constructs (21.3 kilobase pairs,
and 2453, 2318, 2237 base pairs) revealed activation of a
UVC-dependent promoter. Increased FasL promoter activity
after UV irradiation is likely to be mediated by target se-
quences located within the 2453 and 2318 region, as the 2237
construct no longer exhibited strong activation by UV irradia-
tion. Further support for the role in FasL activation of the
MEKK-RE site located within this comes from analysis of 59
promoter sequences mutated within the NF-kB or AP1 sites;
neither was able to completely abrogate UV responsiveness
(Fig. 9B). These results point to the role of MEKK-RL and its
associated proteins in mediating increased FasL transcription.
Indeed, cells expressing the ATF2 construct exhibited a higher
basal level of FasL promoter activity. After UV irradiation, a
further increase of 2–3-fold was noted in the LU1205ATF2 cells
(Fig. 9C). The overall level of FasL protein was also higher in
LU1205/ATF2 cells before and after UVC treatment than in
control cells (Fig. 9D). These observations suggest that ATF2
plays a positive role in the regulation of FasL transactivation/
expression in melanoma (Fig. 9, A–D), as previously observed
in other cell systems (63). Because of blockage by different
inhibitory proteins, including Bcl-2, the presence of both Fas-
receptor and Fas ligand in melanoma cells is necessary but not
sufficient to initiate death signaling. UVC-induced degradation
of Bcl-2 (Fig. 9D) correlates with the progression of apoptosis
seen in these cells. The elevated expression level of FasL in
LU1205/ATF2 cells may explain the higher level of apoptosis
seen after UV irradiation when compared with the apoptosis
seen in cells expressing the truncated form of ATF2.
Melanoma cells are resistant to apoptotic signaling induced
by TNFa, which, as noted, elicits a survival signal in these
cells. Since NF-kB has been implicated in protection against
TNF-mediated apoptosis (64–66), we next examined the pos-
sible effects of ATF2 overexpression on NF-kB DNA binding
activity and transactivation before and after UVC treatment of
melanoma cells. LU1205 cells contain relatively high basal
NF-kB activity (Fig. 10A). An additional increase in DNA bind-
ing activity of NF-kB p65-p50 (Fig. 10B, the upper band of the
specific NF-kB DNA-binding complex) and transactivation of
NF-kB were observed in ATF2- and ATF2D1–195-transfected
cells, both at the basal and at the UVC-induced levels (Fig. 10,
A and B). Increased levels of NF-kB activity after UVC irradi-
ation of ATF2-overexpressing cells, when compared with the
control cells, are due to down-regulation of IkBa levels in these
cells 18 h after UVC treatment (Fig. 10C), possibly as a result
of ATF2-dependent regulation of IkB expression. Since UVC
treatment causes prolonged activation and nuclear transloca-
tion of NF-kB (0.5–20 h) when compared with the short NF-kB
activation in response to TNFa treatment (10–90 min), it is not
FIG. 9. A–C, FasL promoter activity in LU1205/neo and LU1205/ATF2 cells. The reporter constructs used are indicated. D, Western blot analysis
of FasL and Bcl-2 expression in LU1205/neo and LU1205/ATF2 cells following UVC treatment; nonspecific band (ns) from Bcl-2 blot was used as
a reference band for protein loading.
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possible to distinguish between primary and secondary TNF-
mediated activation of NF-kB in melanoma cells. However, the
abundance of NF-kB in these cells, especially in ATF2-overex-
pressing cells, is likely to represent an additional factor that
promotes Fas- versus TNF-mediated apoptosis of late-stage
melanoma cells.
DISCUSSION
The functional role of ATF2 in the regulation of cell death
and survival in human melanoma was evaluated by overex-
pression of its full-size and truncated (without transactivation
domain) forms. Here we provide evidence that both forms of
ATF2 serve as potent accelerators of UVC-induced cell death in
metastatic human melanoma LU1205 cells. Apoptosis follow-
ing UVC treatment and its enhancement by overexpression of
both forms of ATF2 were demonstrated by characteristic
changes in cell morphology, redistribution of phosphatidyl-
serine in the plasma membrane (annexin-V-FITC staining),
activation of caspase cascade, PARP cleavage, and DNA
fragmentation.
Among the important determinants influencing the degree of
ATF2-mediated transactivation are: (i) alternative promoter usage
of the ATF2 gene and differential splicing, which create several
ATF2 isoforms that exhibit different transcriptional output (full-
length ATF2 in its native form is transcriptionally inactive as a
result of inhibitory intramolecular interaction, whereas a 42-kDa
spliced form (D150–248) is constitutively active; Refs. 33 and 44);
(ii) regulation of the transcriptional activity of ATF2, like other
members of the ATF/CREB and Jun/Fos families, by phosphoryla-
tion, including JNK- and p38-directed phosphorylation of threonine
residues at positions 69 and 71 (39, 67- 69); (iii) ATF2 heterodimer-
ization with other proteins of the ATF/CREB and Jun/Fos families,
which results in varying degrees of transcriptional output (41, 46,
47) (ATF2 heterodimerization also plays an important role in its
stability; Ref. 48); and (iv) interaction with the transcriptional co-
activator p300 (dependent on phosphorylation of Ser121), which
contributes to ATF2 transcriptional activity (70). This tight regu-
lation suggests that any of these variables (hypophosphorylation,
altered ratio between different full-length and spliced forms, a
change in the nature of the heterodimers) may suppress ATF2-de-
pendent transcription. Indeed, silencing effects were described for
different ATF2/CREB family members. For example, binding of
CREB and CREM to the AP-1 site inhibited activation by c-Jun
(71), ATF2 down-regulated hepatitis B virus X promoter activity by
competition for the AP-1 binding site and formation of ATF2-Jun
heterodimers (72), and CREB and ATF1 were shown to be potent
inhibitors of several transcription factors (73). The dominant neg-
ative form of CREB efficiently reduced radiation resistance (32),
and inhibited tumor growth and metastatic potential of human
melanoma through squelching of other CREB-associated proteins
(31, 74). The relationship between changes in ATF2-dependent
transactivation after UVC irradiation and the degree of apoptosis,
as demonstrated in the present study, suggest that ATF2 tightly
regulates expression of genes that control apoptosis.
One of the common causes of cell death is down-regulation of
expression and decrease in the concentration within the me-
dium of essential growth factors, for example, death of the
IL-2-dependent CTLL-2 cell line upon deprivation of IL-2 (75).
Late-stage metastatic melanoma cells are characterized by au-
tocrine growth stimulation as a result of production of several
cytokines, including bFGF, IL-6, IL-8, and TNFa (59). Numer-
ous observations indicate that TNFa promotes the metastatic
potential of melanoma cells (12–14) as well as of some other
FIG. 10. A, NF-kB activity in ATF2-
transfected LU1205 cells. LU1205/neo,
LU1205/ATF2, and LU1205/ATF2D1–195
cells were transiently transfected with ei-
ther 4xNF-kB-CAT or with the empty vec-
tor pBL4-CAT in the presence of pCMV-
b-gal. Two days after transfection, cells
were irradiated with UVC and protein ex-
tracts were prepared 18 h later. The pro-
tein concentration of extracts was nor-
malized based on b-gal activity. Relative
CAT activity is indicated. B, electro-
phoretic mobility shift assay of nuclear
extracts of control and LU1205/ATF2
cells 3 h after UVC irradiation was per-
formed as described previously (29). The
positions of NF-kB DNA-binding com-
plexes are indicated by arrows; the upper
bands represent the p65-p50 het-
erodimer, the intermediate band reflects
the p50-p50 complex, and the lower band,
nonspecific binding (ns). C, Western blot
analysis of IkBa levels in the respective
melanoma cell lines 18 h after UVC
treatment.
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tumors (10, 76–78). Down-regulation of c-KIT levels in mela-
noma cells has been implicated in the enhancement of mela-
noma tumorigenicity and metastasis (79). Although the effect
of TNFa on negative regulation of c-KIT expression in mela-
noma has not been determined, it has been described for nor-
mal bone marrow progenitor cells and myeloid leukemia cells
(80, 81). In general, TNFa plays a dual role in the regulation of
cell death and survival. This cytokine is an essential growth
factor not only for metastatic, but also for normal, cells in
certain circumstances, e.g. in immature thymocytes (82). On
the other hand, this cytokine induces apoptosis of some tumor
cell lines and elicits an unusually wide range of biological
responses (7–9). Expression of the TNFa gene is regulated by
different transcription factors, including AP-1, ATF2, NFAT,
Erg-1, C/EBPb, and NF-kB (18–22). The present study demon-
strated the ability to modulate TNFa transcription using both
full-length and truncated forms of ATF2, resulting in increased
susceptibility of UV-treated melanoma cells to programmed
death. The dominant negative form of c-Jun (TAM 67) (53) also
had a similar effect, further indicating that down-regulation of
TNFa transcription could be due to heterodimerization of in-
active ATF2 with c-Jun. In contrast, overexpression of func-
tionally active c-Jun allowed the negative effect of ATF2 on
TNFa expression to be overcome and partially rescued UV- and
ATF2-mediated apoptosis, suggesting that ATF2 silences the
c-Jun contribution to TNFa expression.
The present study also demonstrates that UVC-induced ap-
optosis of LU1205 as well as ATF2-transfected LU1205 cells is
mediated by Fas death signaling. The role of Fas signaling in
radiation-induced apoptosis was described in several normal
and tumor cell systems (83–87). It was also demonstrated that
UVC irradiation by itself may initiate trimerization of the Fas
receptor and induction of signaling, substituting FasL (83, 87).
However, it is still unresolved whether UVC-induced Fas tri-
merization per se is sufficient to mediate apoptosis, as it is
difficult to exclude other cellular changes elicited by UV irra-
diation. Melanoma cells expressing full-length ATF2 were
found to express higher levels of FasL protein, which may also
contribute to Fas-mediated apoptosis, as was shown in UV-
induced apoptosis of human lymphocytes (63, 84). Elevated
FasL expression may explain the higher degree of apoptosis
seen after UV irradiation of melanoma cells that express full-
length ATF2 versus truncated form, as, in addition to silencing
TNF, by both forms of ATF2, only the full-length form appears
capable of mediating positive transcriptional signals. The abil-
ity of full-length ATF2 to elicit a negative signal in the case of
TNFa and a positive signal in the case of FasL may be due to
its heterodimerized partner, the overall contribution of neigh-
boring transcription factors on a given promoter, and a possible
requirement for the contribution of co-activators. Clearly, the
effects of full-length ATF2 as a transcription factor are im-
paired due to its poor phosphorylation. We did not, however,
complete analysis of all spliced forms of ATF2 expressed in
these melanoma cells and thus cannot exclude further inter-
play between themselves and other bZIP partners.
The resistance of cells against TNF-mediated killing is
linked to NF-kB expression (9, 64–66). Metastatic melanoma
LU1205 cells, used in the present study, are also characterized
by moderate NF-kB activity that may provide resistance
against TNFa-mediated apoptosis. Indeed, inhibition of NF-kB
activity by IkBD transformed TNFa from a protective to a
death factor.2
Our data extend previous findings regarding down-regula-
tion of radioresistance in human melanoma MeWo cells by
truncated forms of CREB and ATF2 (32, 36). We have shown in
the present study that the truncated form of ATF2 increased
UVC-induced apoptosis. Thus, an elevated level of apoptosis
coincides with reduced resistance to UV irradiation. Surpris-
ingly, comparison of ATF2D1–195 with full-length ATF2 over-
expression revealed that while both elicit equally efficient si-
lencing of TNFa expression, full-length ATF2 was more
efficient in elevating UV-mediated apoptosis, possibly because
of its ability to increase expression of FasL, which boosts death
signaling in these melanoma cells. This is unlike the effect of
full-length ATF2 in early stage melanoma cells DM3211, i.e. an
increase radiation resistance (36), suggesting that the impact
of ATF2 on cell survival depends on its proper activation and
interaction with other factors that have been altered during
melanoma progression. Indeed, the balance between various
ATF2 forms, c-Jun, and other members of the CREB/ATF and
AP-1 families is expected to change during melanoma develop-
ment as was previously shown in the B16 mouse melanoma
model (88).
In summary, we established an inverse correlation between
TNFa expression as a survival factor and the consequences of
Fas-mediated death signaling in melanoma cells. Our findings
provide the foundation for design of ATF2-based reagents that
could be useful in altering the rate of irradiation-mediated
programmed death of melanoma cells.
Acknowledgments—We thank Drs. M. Green, P. Herrlich, P. Angel,
H. van Dam, C. V. Paya, S. Kasibhatla, D. Ballard, J. S. Economou, and
M. J. Birrer for providing plasmid constructs; Dr. M. Herlyn for LU1205
melanoma cells; and Drs. V. Adler and S. Fuchs for discussion.
REFERENCES
1. Nagata, S. (1997) Cell 88, 355–365
2. Thompson, C. B. (1995) Science 67, 1456–1462
3. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. M., van Elsas, A.,
Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. (1998) Nat. Med.
4, 232–234
4. Chin, L., Merlino, G., and DePinho, R. A. (1998) Genes Dev. 12, 3467–3481
5. Nicholson, D. W., and Thornberry, N. A. (1997) Trends Biochem. Sci. 22,
299–306
6. Salvesen, G. S., and Dixit, V. M. (1997) Cell 91, 443–446
7. Hsu, H., Shu, H., Pan, M., and Goeddel, D. V. (1996) Cell 84, 299–308
8. Lee, S. Y., Reichlin, A., Santana, A., Sokol, K. A., and Nussenzweig, M. C.
(1998) Immunity 7, 703–713
9. Liu, Z., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565–576
10. Orosz, P., Kruger, A., Hubbe, M., Ruschoff, J., Von Hoegen, P., and Mannel,
D. N. (1995) Int. J. Cancer 60, 867–871
11. Orosz, P., Echtenacher, B., Falk, W., Ruschoff, J., Weber, D., and Mannel,
D. N. (1993) J. Exp. Med. 177, 1391–1398
12. Cubillos, S., Scallon, B., Feldmann, M., and Taylor, P. (1997) Anticancer Res.
17, 2207–2211
13. Hakansson, A., Gustafsson, B., Krysander, L., Bergenwald, C., Sander, B., and
Hakansson, L. (1997) Melanoma Res. 7, 139–145
14. Miele, M. E., Bennett, C. F., Miller, B. E., and Welch, D. R. (1994) Exp. Cell
Res. 214, 231–241
15. Ashkenazi, A., and Dixit, V. M. (1998) Science 281, 1305–1308
16. Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldvin, A. S.,
Jr. (1998) Science 281, 1680–1683
17. Natoli, G., Costanzo, A., Guido, F., Moretti, F., Bernardo, A., Burgio, V. L.,
Agresti, C., and Levrero, M. (1998) J. Biol. Chem. 273, 31262–31272
18. Newell, C. L., Deisseroth, A. B., and Berestein, G. (1994) J. Leukocyte Biol. 56,
27–35
19. Rhoades, K. L., Golub, S. H., and Economou, J. S. (1992) J. Biol. Chem. 267,
22102–22107
20. Tsai, E. Y., Jain, J., Pesavento, P. A., Rao, A., and Goldfeld, A. E. (1996) Mol.
Cell. Biol. 16, 459–467
21. Yao, J., Mackman, N., Edgington, T. S., and Fan, S. T. (1997) J. Biol. Chem.
272, 17795–17801
22. Zagariya, A., Mungre, S., Lovis, R., Birrer, M., Ness, S., Thimmapaya, B., and
Pope, R. (1998) Mol. Cell. Biol. 18, 2815–2824
23. Holtz-Heppelmann, C. J., Algeciras, A., Badley, A. D., and Paya, C. V. (1998)
J. Biol. Chem. 273, 4416–4423
24. Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and
Green, D. R. (1998) Mol. Cell 1, 543–551
25. Latinis, K. M., Carr, L. L., Peterson, E. J., Norian, L. A., Eliason, S. L., and
Koretzky, G. A. (1997) J. Immunol. 158, 4602–4611
26. Mittelstadt, P. R., and Ashwell, J. D. (1998) Mol. Cell. Biol. 18, 3744–3751
27. Osborne, B. A. (1996) Curr. Opin. Immunol. 8, 245–254
28. Bossy-Wetzel, E., Bakiri, L., and Yaniv, M. (1997) EMBO J. 16, 1695–1709
29. Ivanov, V. N., and Nikolic-Zugic, J. (1997) J. Biol. Chem. 272, 8558–8566
30. Schreiber, M., Baumann, B., Cotten, M., Angel, P., and Wagner, E. F. (1995)2 V. N. Ivanov and Z. Ronai, unpublished observations.
ATF2 in UVC-induced Apoptosis14088
EMBO J. 14, 5338–5349
31. Xie, S., Price, J. E., Luca, M., Jean, D., Ronai, Z., and Bar-Eli, M. (1997)
Oncogene 15, 2069–2075
32. Yang, Y. M., Dolan, L., and Ronai, Z. (1996) Oncogene 12, 2223–2233
33. Li, X., and Green, M. R. (1996) Genes Dev. 10, 517–527
34. Liu, F., and Green, M. R. (1990) Cell 61, 1217–1224
35. Liu, F., and Green, M. R. (1994) Nature 368, 520–525
36. Ronai, Z., Yang, Y., Fuks, S. Y., Adler, V., Sardana, M., and Herlyn, M. (1998)
Oncogene 16, 523–531
37. Bender, K., Blattner, C., Knebel, A., Iordanov, M., Herrlich, P., and Rahms-
dorf, H.-J. (1997) J. Photochem. Photobiol. B 37, 1–17
38. Minden, A., and Karin, M. (1997) Biochim. Biophys. Acta 1333, F85–F104
39. Van Dam, H., Wilhelm, D., Herr, I., Steffen, A., Herrlich, P., and Angel, P.
(1995) EMBO J. 14, 1798–1811
40. Du, W., Thanos, D., and Maniatis, T. (1993) Cell 74, 887–898
41. De Cesare, D., Vallone, D., Caracciolo, A., Sassone-Corsi, P., Nerlov, C., and
Verde, P. (1995) Oncogene 11, 365–376
42. Kim, S. J., Wagner, S., Liu, F., O’Reilly, M. A., Robbins, P. D., and Green, M. R.
(1992) Nature 358, 331–334
43. Narayan, S., Beard, W. A., and Wilson, S. H. (1995) Biochemistry 34, 73–80
44. Georgopoulos, K., Morgan, B. A., and Moore, D. D. (1992) Mol. Cell. Biol. 12,
747–757
45. Chatton, B., Bocco, J. L., Goetz, J., Gaire, M., Lutz, Y., and Kedinger, C. (1994)
Oncogene 9, 375–385
46. Hai, T., and Curran, T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3720–3724
47. Van Dam, H., Duyndam, M., Rottier, R., Bosch, A., De Vries-Smith, L., Her-
rlich, P., Zantema, A., Angel, P., and Van der Eb, A. (1993) EMBO J. 12,
479–487
48. Fuchs, S. Y., and Ronai, Z. (1999) Mol. Cell. Biol. 19, in press
49. Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y.,
and Ballard, D. W. (1995) Mol. Cell. Biol. 15, 2809–2818
50. Van Dam, H., Huguier, S., Kooistra, K., Baguet, J., Vial, E., van der Eb, A. J.,
Herrlich, P., Angel, P., and Castellazzi, M. (1998) Genes Dev. 12, 1227–1239
51. Treier, M., Staszewski, L. M., and Bohmann, D. (1994) Cell 78, 787–798
52. Brown, P. H., Alani, R., Preis, L. H., Szabo, E., and Birrer, M. J. (1993)
Oncogene 8, 877–886
53. Brown, P. H., Chen, T. K., and Birrer, M. J. (1994) Oncogene 9, 791–799
54. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C.
(1991) J. Immunol. Methods 139, 271–279
55. Krasilnikov, M. A., Adler, V., Fuchs, S. Y., Dong, Z., Haimovitz-Friedman, A.,
Herlyn, M., and Ronai, Z. (1999) Mol Carcinog. 24, 64–69
56. Verhoven, B., Schlegel, R. A., and Williamson, P. (1995) J. Exp. Med. 182,
1597–1601
57. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K.,
Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Mun-
day, N. A., Raju, S. M., Smulson, M. E., Yamin, T., Yu, V. L., and Miller,
D. K. (1995) Nature 376, 37–43
58. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and
Schreiber, S. L. (1995) Science 268, 726–731
59. Rodeck, U. (1993) Cancer Metastasis Rev. 12, 219–226
60. Duckett, C. S., and Thompson, C. B. (1997) Genes Dev. 11, 2810–2821
61. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E.,
Schneider, P., Bornand, T., Fontana, A., Lienaro, D., Cerottini, J.-C., and
Tschopp, J. (1996) Science 274, 1363–1366
62. Latinis, K. M., Norian, L. A., Eliason, S. L., and Koretzky, G. A. (1997) J. Biol.
Chem. 272, 31427–31434
63. Faris, M., Latinis, K. M., Kempiak, S. J., Koretzky, G. A., and Nel, A. (1998)
Mol. Cell. Biol. 18, 5414–5424
64. Beg, A. A., and Baltimore, D. (1996) Science 274, 782–784
65. Wang, C., Mayo, M. W., and Baldwin, A. S. (1996) Science 274, 784–787
66. Van Antwerp, D. J., Martin, S. J., Ka, T., Green, D. R., and Verma, I. M. (1996)
Science 274, 787–789
67. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. (1995) Science 267,
389–393
68. Hazzalin, C. A., Cano, E., Cueda, A., Barratt, M. S., Cohen, P., and Ma-
hadevan, L. C. (1996) Curr. Biol. 6, 1028–1031
69. Livingstone, C., Patel, G., and Jones, N. (1995) EMBO J. 14, 1785–1797
70. Kawasaki, H., Song, J., Eckner, R., Ugai, H., Chiu, R., Taira, K., Shi, Y., Jones,
N., and Yokoyama, K. K. (1998) Genes Dev. 12, 233–245
71. Masquilier, D., and Sassone-Corsi, P. (1992) J. Biol. Chem. 267, 22460–22466
72. Choi, C. Y., Choi, B. H., Park, G. T., and Rho, H. M. (1997) J. Biol. Chem. 272,
16934–16939
73. Lemaigre, F. P., Ace, C. I., and Green, M. R. (1993) Nucleic Acids Res. 21,
2907–2911
74. Deng, G., and Podack, E. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,
2189–2193
75. Jean, D., Harbison, M., McConkey, D. J., Ronai, Z., and Bar-Eli, M. (1998)
J. Biol. Chem. 273, 24884–24890
76. Qin, Z., Kruger-Krasagakes, S., Kunzendorf, U., Hock, H., Diamantstein, T.,
and Blankenstein, T. (1993) J. Exp. Med. 178, 355–360
77. Stoelcker, B., Hafner, M., Orosz, P., Nieswandt, B., and Mannel, D. N. (1995)
J. Inflamm. 46, 155–167
78. Wu, S., Boyer, C. M., Whitaker, R. S., Berchuck, A., Wiener, J. R., Weinberg,
J. B., and Bast, R. C., Jr. (1993) Cancer Res. 53, 1939–1944
79. Huang, S., Jean, D., Luca, M., Tainsky, M. A., and Bar-Eli, M. (1998) EMBO
J. 17, 4538–4369
80. Khoury, E., Andre, C., Pontvert-Delucq, S., Drenou, B., Baillou, C., Guigon, M.,
Najman, A., and Lemoine, F. M. (1994) Blood 84, 2506–2514
81. Rusten, L. S., Smeland, E. B., Jacobsen, F. W., Lien, E., Lesslauer, W., Dubois,
C. M., and Jacobsen, S. E. (1994) J. Clin. Invest. 94, 165–172
82. Zuniga-Pflucker, J. C., Di, J., and Lenardo, M. J. (1995) Science 268,
1906–1909
83. Aragane, Y., Kulmus, D., Metze, D., Wilkes, G., Poppelmann, B., Luger, T. A.,
and Schwarz, T. (1998) J. Cell Biol. 140, 171–182
84. Caricchio, R., Reap, E. A., and Cohen, P. L. (1998) J. Immunol. 161, 241–251
85. Leverkus, M., Yaar, M., and Gilchrest, B. A. (1997) Exp. Cell Res. 232, 255–262
86. Reap, E. A., Roof, K., Maynor, K., Borrero, M., Booker, J., and Cohen, P. L.
(1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5750–5755
87. Rehemtulla, A., Hamilton, C. A., Chinnaiyan, A. M., and Dixit, V. M. (1997)
J. Biol. Chem. 272, 25783–25786
88. Rutberg, S. E., Goldstein, I. M., Yang, Y. M., Stackpole, C. W., and Ronai, Z.
(1994) Mol. Carcinogenesis 10, 82–87
ATF2 in UVC-induced Apoptosis 14089
